Shanghai Kaibao Pharmaceutical CO.,Ltd (SHANGHAI KAIBAO PHARM CO LTD) Aktie
300039.SZ
Verzögert 15 Min.SHANGHAI KAIBAO PHARM CO LTD
Market Cap
$5,198,619,648
Über Shanghai Kaibao Pharmaceutical CO.,Ltd (SHANGHAI KAIBAO PHARM CO LTD) Aktie
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and respiratory infections; and Phlegm-Heat Clearing Capsules to clear heat, resolve phlegm, and detoxifying. It also provides liver-protecting products, including Thiopronine for injection and Thiopronine enteric-coated tablets. In addition, the company provides Astragalus and Ginseng Capsules for the treatment of cardiovascular and cerebrovascular diseases. Further, it offers diclofenac sodium enteric-coated tablets; artificial bezoar metronidazole capsules; Mai'an granules; Loquat cough granules that clears the lungs, relieves cough, and reduces phlegm; compound danshen tablets; Tongmai granules; pediatric pharyngeal granules; stroke rejuvenation pills; and Xiao Chai Hu granules which relieves exterior syndromes, clears heat, soothes the liver, and harmonizes the stomach. Further, the company provides Alopecia areata; Bear bile drops that clears heat, calms the liver, and improves eyesight, as well as used for infantile convulsions and sore throat; and Shanhaidan capsules. The company was founded in 2000 and is based in Shanghai, China.
Unternehmensinformationen
201401 Shanghai, China
Analystenempfehlungen
Diese Übersicht gibt einen schnellen Einblick, wie Analysten das Aktienpotenzial basierend auf ihren neuesten Analysen und Kurszielen bewerten.